Literature DB >> 12902343

Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains.

Dawn L Duval1, Annie Jean, Arthur Gutierrez-Hartmann.   

Abstract

Pit-1 and Ets-1 binding to a composite element synergistically activates and targets Ras-mitogen-activated protein kinase signaling to the rat prolactin promoter. These transcriptional responses appear to depend on three molecular features: organization of the Ets-1/Pit-1 composite element, physical interaction of these two factors via the Pit-1 homeodomain (amino acids 199-291) and the Ets-1 regulatory III domain (amino acids 190-257), and assembly of their transcriptional activation domains (TADs). Here we show that the organization of the Ets-1/Pit-1 composite element tolerates significant flexibility with regard to Ras stimulation and synergy. Specifically, the putative monomeric Pit-1 binding site can be substituted with bona fide binding sites for either a Pit-1 monomer or dimer, and these sites tolerated a separation of 28 bp. Additionally, we show that the physical interaction of Ets-1 and Pit-1 is not required for Ras responsiveness or synergy because block mutations of the Pit-1 interaction surface in Ets-1, which reduced Ets-1/Pit-1 binding in vitro, did not significantly affect Ets-1 stimulation of Ras responsiveness or synergy. We also show differential use of distinct TAD subtypes and Pit-1 TAD subregions to mediate either synergy or Ras responsiveness. Specifically, TADs from Gal4, VP16, or Ets-2 regulatory III domain linked to Ets-1 DNA binding domain constructs restored synergy to these TAD/Ets-1 DNA binding domain fusions. Conversely, deletion of the defined Pit-1 TAD (amino acids 2-80) retained synergy, but not Ras responsiveness. Consequently, we further defined the Pit-1 amino-terminal TAD into region 1 (R1, amino acids 2-45) and region 2 (R2, amino acids 46-80). R1 appears to regulate basal and synergistic responses, whereas the Ras response was mapped to R2. In summary, Ras responsiveness and Pit-1/Ets-1 synergy are mediated through the assembly of distinct TADs at a flexible composite element, indicating that different mechanisms underlie these two transcriptional responses and that the Pit-1 R2 subregion represents a novel, tissue-specific Ras-responsive TAD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902343     DOI: 10.1074/jbc.M302433200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  The 26-amino acid beta-motif of the Pit-1beta transcription factor is a dominant and independent repressor domain.

Authors:  Matthew D Jonsen; Dawn L Duval; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2009-06-25

2.  CEBPD suppresses prolactin expression and prolactinoma cell proliferation.

Authors:  Yunguang Tong; Jin Zhou; Jun Mizutani; Hidenori Fukuoka; Song-Guang Ren; Arthur Gutierrez-Hartmann; H Phillip Koeffler; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2011-10-06

3.  Promoter activation by the varicella-zoster virus major transactivator IE62 and the cellular transcription factor USF.

Authors:  Min Yang; Hua Peng; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells.

Authors:  Mai Koizumi Ichikawa; Kaori Endo; Yuka Itoh; Asami Hotta Osada; Yujiro Kimura; Koichiro Ueki; Kunio Yoshizawa; Keiji Miyazawa; Masao Saitoh
Journal:  FEBS Open Bio       Date:  2022-04-29       Impact factor: 2.792

5.  A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter.

Authors:  Annie Jean; Arthur Gutierrez-Hartmann; Dawn L Duval
Journal:  Mol Endocrinol       Date:  2009-11-03

6.  Transcription factor Ets1 cooperates with estrogen receptor α to stimulate estradiol-dependent growth in breast cancer cells and tumors.

Authors:  Brian T Kalet; Sara R Anglin; Anne Handschy; Liza E O'Donoghue; Charles Halsey; Laura Chubb; Christopher Korch; Dawn L Duval
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.